Home / Contract Awards / DoD Awards Ology Bioservices $135M in Medical Countermeasure Dev’t Contracts

DoD Awards Ology Bioservices $135M in Medical Countermeasure Dev’t Contracts

Ology Bioservices has secured a pair of contracts worth $135.4M combined from the Department of Defense to develop a medical countermeasure against biological threats and a technology platform for producing nucleic acids.

The Alachua, Fla.-based biopharmaceutical company said Monday it will explore the use of monoclonal antibodies as a potential treatment for Yersinia pestis, the bacterium that causes plague, under a contract valued at $130.3M over 10 years.

Team members for the project are the Duke Human Vaccine Institute, Battelle, Just Biotherapeutics, Mapp Biopharmaceutical, Cato Research, Certara and the U.S. Army Medical Research Institute of Infectious Diseases.

Under the second contract, valued at $5.1M, Ology Bioservices will create a manufacturing technology prototype to produce plasmid DNA for potential use in genetic vaccines and gene therapy.

The 30-month agreement contains options for the company to facilitate the development of RNA manufacturing platforms.

DoD’s Platforms for Rapid Integrated Solutions for Medical Countermeasures office awarded the two contracts.

Check Also

Northrop Completes JPSS-2 Microwave Instrument Assembly; Bob Mehltretter Quoted

Northrop Grumman (NYSE: NOC) has assembled a microwave instrument for the second Joint Polar Satellite System being built to support weather forecasting and climate monitoring efforts at the National Oceanic and Atmospheric Administration. The company began testing JPSS-2's Advanced Technology Microwave Sounder to determine whether the technology can withstand environmental conditions during liftoff and in space, NASA said Thursday.

Former Kforce, SES Exec Patrick Sullivan Joins Aptive as Digital Services VP

Patrick Sullivan, formerly vice president of emerging technologies at SES, has joined consulting services provider Aptive Resources as VP of digital services, FedHealthIT reported Thursday.